[Edaily Reporter KIM JI-WAN ] GemVax & KAEL Co.,Ltd. announced the results of a 72-week clinical trial for “GV1001,” a candidate drug for progressive supranuclear palsy (PSP), in London, UK. At the event, the company engaged with international researchers and patient groups and announced plans to incorporate methods for evaluating disease progression using biomarkers into its upcoming global clinical trials.

GemVax & KAEL Co.,Ltd.(082270)The company announced on the 9th that it participated as a Gold Sponsor—a major sponsor—at the international research symposium “Neuro 2026,” held in London on the 5th and 6th (local time). At the event, it presented a poster showcasing the results of an open-label extension study of the Phase 2a clinical trial, which examined the long-term safety and efficacy of GV1001 in PSP patients. This study extended the observation period beyond the previous clinical trial to include evaluation results spanning 72 weeks.

According to the U.S. National Institute of Neurological Disorders and Stroke (NINDS), a common early symptom in PSP patients is losing balance while walking, and they may suddenly fall for no apparent reason. As the disease progresses, patients find it difficult to move their gaze up and down and may move their head instead of their eyes to look in different directions.

Neuro2026 is an international research symposium on progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) co-hosted by CurePSP in the U.S. and the PSP Association (PSPA) in the U.K. Founded in 1990, CurePSP supports patients and their families and funds research to identify the causes of the disease and develop treatments. Established in 1994, the PSP Association in the UK provides counseling for patients and families, operates regional support networks, and is responsible for training medical professionals to facilitate early diagnosis.

This year’s event was attended by researchers, clinicians, and representatives from pharmaceutical and biotech companies from around the world. Participants discussed biomarkers for early diagnosis, the impact of neuroinflammation and genetic factors on disease onset, as well as ongoing clinical trials and strategies for developing new treatments in various countries.

Christophe Diaz, CEO of Cure PSP, said, “As a Gold Sponsor of Neuro 2026, we thank GemVax & KAEL Co.,Ltd. for its continued commitment to the PSP community,” adding, “This collaboration will play a pivotal role in accelerating the research and development of treatments for PSP patients and their families.”

GemVax & KAEL Co.,Ltd. stated, “It is meaningful for us to participate as a main sponsor at Neuro 2026, where PSP experts and patient organizations from around the world have gathered, and to announce the long-term clinical results of GV1001.” The company added, “We will proceed with subsequent global clinical development by carefully incorporating the global clinical development strategies and biomarker-based disease assessment discussed at this symposium.”